APLP2

Across TCGA pan-cancer cohorts, APLP2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated APLP2 data layer compared with 22 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher APLP2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated APLP2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and GBM show a favorable association.

CCRCC, HNSC, and PDAC are the cancer types where APLP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	II,III,IV	0.332	0.773	.004	32	view →
HNSC	DFS	Median	II,III,IV	0.990	0.902	.007	13	view →
PDAC	DFS	Quartile	All	0.599	0.837	.015	13	view →
GBM	DFS	Tertile	All	0.806	0.620	.002	7	view →
LSCC	DFS	Quartile	All	0.507	1.000	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

APLP2–CCRCC (DFS)

Open the CCRCC breakdown →